Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% |
|
-.--% | -.--% |
Fiscal Period: February | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 8.97B | 10.81B | 11.77B | 12.85B | 13.35B | |||||
Total Revenues | 8.97B | 10.81B | 11.77B | 12.85B | 13.35B | |||||
Cost of Goods Sold, Total | 1.26B | 1.8B | 2.04B | 2.27B | 2.48B | |||||
Gross Profit | 7.72B | 9.01B | 9.72B | 10.58B | 10.87B | |||||
Selling General & Admin Expenses, Total | 3.68B | 4.73B | 4.72B | 5.07B | 5.43B | |||||
R&D Expenses | 1.98B | 2.52B | 2.82B | 3.06B | 3.32B | |||||
Other Operating Expenses, Total | 5.66B | 7.26B | 7.53B | 8.13B | 8.75B | |||||
Operating Income | 2.06B | 1.76B | 2.19B | 2.45B | 2.12B | |||||
Interest Expense, Total | -134M | -149M | -204M | -252M | -304M | |||||
Interest And Investment Income | 161M | 60M | 7M | 2M | 65M | |||||
Net Interest Expenses | 27M | -89M | -197M | -250M | -239M | |||||
Currency Exchange Gains (Loss) | - | 31M | 31M | - | 15M | |||||
Other Non Operating Income (Expenses) | 7M | 24M | -4M | 10M | -6M | |||||
EBT, Excl. Unusual Items | 2.09B | 1.72B | 2.02B | 2.21B | 1.89B | |||||
Restructuring Charges | -9M | -79M | -42M | -1M | -8M | |||||
Merger & Related Restructuring Charges | - | - | - | -63M | -87M | |||||
Gain (Loss) On Sale Of Investments | 799M | 31M | 172M | -41M | - | |||||
Legal Settlements | - | -237M | 237M | - | - | |||||
Other Unusual Items | - | - | -8M | -21M | - | |||||
EBT, Incl. Unusual Items | 2.88B | 1.44B | 2.38B | 2.08B | 1.79B | |||||
Income Tax Expense | 461M | -4.92B | 324M | 265M | 478M | |||||
Earnings From Continuing Operations | 2.42B | 6.36B | 2.06B | 1.82B | 1.31B | |||||
Net Income to Company | 2.42B | 6.36B | 2.06B | 1.82B | 1.31B | |||||
Minority Interest | - | 56M | - | - | - | |||||
Net Income - (IS) | 2.42B | 6.41B | 2.06B | 1.82B | 1.31B | |||||
Net Income to Common Incl Extra Items | 2.42B | 6.41B | 2.06B | 1.82B | 1.31B | |||||
Net Income to Common Excl. Extra Items | 2.42B | 6.41B | 2.06B | 1.82B | 1.31B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.94 | 15.37 | 4.9 | 4.34 | 3.11 | |||||
Basic EPS - Continuing Operations | 5.94 | 15.37 | 4.9 | 4.34 | 3.11 | |||||
Basic Weighted Average Shares Outstanding | 408M | 417M | 420M | 420M | 423M | |||||
Net EPS - Diluted | 5.85 | 15.08 | 4.86 | 4.31 | 3.09 | |||||
Diluted EPS - Continuing Operations | 5.85 | 15.08 | 4.86 | 4.31 | 3.09 | |||||
Diluted Weighted Average Shares Outstanding | 414M | 425M | 423M | 422M | 426M | |||||
Normalized Basic EPS | 3.21 | 2.72 | 3.01 | 3.29 | 2.79 | |||||
Normalized Diluted EPS | 3.16 | 2.66 | 2.99 | 3.27 | 2.77 | |||||
American Depositary Receipts Ratio (ADR) | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.43B | 2.28B | 2.78B | 3.04B | 2.71B | |||||
EBITA | 2.22B | 2.06B | 2.52B | 2.75B | 2.37B | |||||
EBIT | 2.06B | 1.76B | 2.19B | 2.45B | 2.12B | |||||
EBITDAR | 2.57B | 2.46B | 2.98B | 3.25B | 2.92B | |||||
Total Revenues (As Reported) | 8.97B | 10.81B | 11.77B | 12.85B | 13.35B | |||||
Effective Tax Rate - (Ratio) | 15.99 | -342 | 13.6 | 12.71 | 26.67 | |||||
Current Domestic Taxes | 212M | 123M | 230M | 66M | 446M | |||||
Current Foreign Taxes | 136M | 240M | 246M | 279M | 250M | |||||
Total Current Taxes | 348M | 363M | 476M | 345M | 696M | |||||
Deferred Domestic Taxes | 121M | -263M | -33M | 51M | -132M | |||||
Deferred Foreign Taxes | -8M | -5.02B | -119M | -131M | -86M | |||||
Total Deferred Taxes | 113M | -5.28B | -152M | -80M | -218M | |||||
Normalized Net Income | 1.31B | 1.13B | 1.26B | 1.38B | 1.18B | |||||
Interest on Long-Term Debt | 129M | 145M | 202M | 241M | 305M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 28M | 25M | 33M | 35M | 24M | |||||
Selling and Marketing Expenses | 2.92B | 3.68B | 3.71B | 4.07B | 4.39B | |||||
General and Administrative Expenses | 764M | 1.06B | 1B | 1B | 1.04B | |||||
Research And Development Expense From Footnotes | 1.98B | 2.52B | 2.82B | 3.06B | 3.32B | |||||
Net Rental Expense, Total | 145M | 179M | 202M | 204M | 214M | |||||
Imputed Operating Lease Interest Expense | 36.68M | 39.14M | 51.9M | 41.47M | 41.19M | |||||
Imputed Operating Lease Depreciation | 108M | 140M | 150M | 163M | 173M | |||||
Stock-Based Comp., COGS (Total) | 52M | 97M | 119M | 114M | 132M | |||||
Stock-Based Comp., R&D Exp. (Total) | 371M | 459M | 524M | 528M | 616M | |||||
Stock-Based Comp., S&M Exp. (Total) | 203M | 293M | 322M | 302M | 376M | |||||
Stock-Based Comp., G&A Exp. (Total) | 105M | 168M | 157M | 131M | 166M | |||||
Total Stock-Based Compensation | 731M | 1.02B | 1.12B | 1.08B | 1.29B |
- Stock Market
- Equities
- VMW Stock
- BZF1 Stock
- Financials VMware, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition